Virbac

VIRP

FR0000031577

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:24 2025-06-18 am EDT			5-day change	1st Jan Change
319.00 ^EUR	+0.63%		-1.54%	+0.79%

Apr. 16	VIRBAC : Decent Q1; Clarity on US tariff exposure was a key takeaway
Apr. 16	VIRBAC : Stifel still buying after Q1 results	CF

Virbac SA Provides Revenue Guidance for the Year 2025

Published on 01/16/2025 at 11:45

Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%.

Latest news about Virbac

VIRBAC : Decent Q1; Clarity on US tariff exposure was a key takeaway	Apr. 16
VIRBAC : Stifel still buying after Q1 results	Apr. 16	CF
French and Benelux stocks-Factors to watch	Apr. 16	RE
Virbac: Q1 sales up 8.5%	Apr. 15	CF
Virbac Q1 Revenue EUR 375.2 Million	Apr. 15	RE
Virbac Q1 2025 Revenue EUR 375.2 Mln	Apr. 15	RE
Virbac: surrounded on the back of a broker upgrade	Mar. 17	CF
VIRBAC : Oddo BHF remains 'neutral', confirms its target	Mar. 17	CF
VIRBAC : 2024 profitability somewhat exceeded expectations; stock re-rating underway	Mar. 17
VIRBAC : Stifel raises its recommendation	Mar. 17	CF
Virbac SA Seeks Acquisitions	Mar. 14	CI
Virbac SA, 2024 Earnings Call, Mar 14, 2025	Mar. 14
French and Benelux stocks-Factors to watch	Mar. 14	RE
Virbac: 20% increase in consolidated net income by 2024	Mar. 13	CF
Virbac SA Provides Financial Guidance for the Fiscal 2025	Mar. 13	CI
Virbac SA Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 12	CI
VIRBAC : 2024 top-line goals met; uninspiring 2025 outlook could be raised later	Jan. 17
Oddo BHF Downgrades Virbac to Neutral, Cuts PT	Jan. 17	MT
Virbac forecasts sales growth of 4 to 6% in 2025	Jan. 16	RE
Virbac SA Provides Revenue Guidance for the Year 2025	Jan. 16	CI
Virbac SA Reports Non-Audited Consolidated Revenue Results for the Fourth Quarter and Full Year Ended December 2024	Jan. 16	CI
A poor 2024 increases the odds of a brighter 2025	Jan. 02
Virbac SA's Equity Buyback announced on December 19, 2024 has expired.	Dec. 18	CI
Virbac Buys Turkish Animal Health Product Distributor Mopsan	Dec. 03	MT
Virbac SA acquired Mopsan Veteriner Urunleri A.S.	Dec. 02	CI

Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (61.6%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (38.4%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (40.8%), Latin America (15.9%), North America (13%), India/Africa/Middle East (12.5%), East Asia (10.1%) and Pacific (7.7%).

Employees

6,365

Sector

Pharmaceuticals

Calendar

Jun. 18 - Annual General Meeting

More about the company